MedTrace Logo

Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients

NCT00481637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2019-04-17

No results posted yet for this study

Summary

The purpose of this study is to study whether immune cells capable of killing tumors that express proteins associated with paraneoplastic neurologic syndrome (PNS) can be found in small cell lung cancer and ovarian cancer patients. The presence of these cells may play a role in tumor immunity in these patients. The protocol involves neurological examinations and collection of blood.

Conditions

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Robert Darnell, MD, PHD · Rockefeller University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481637 on ClinicalTrials.gov